No abstract

RESUMOObjetivo: Validar um modelo de obesidade induzida por dieta hiperlipídica, de baixo custo, fácil reprodutibilidade, que mimetizasse características observadas no humano e viabilizasse posteriores proposições terapêuticas. Materiais e métodos: Dezesseis camundongos Swiss receberam dieta padrão (DP) ou dieta hiperlipídica (DH), durante 10 semanas. Resultados: Embora o grupo DP tenha apresentado maior consumo de água (p < 0,01) e ração (p < 0,001), o grupo DH apresentou maior ganho de peso corpóreo (p < 0,5) e aumento de coxins adiposos (p < 0,001), favorecendo maior índice de adiposidade (p < 0,001), glicemia (p < 0,01) e área sob a curva nos testes de tolerância à insulina (p < 0,001) e à glicose (p < 0,01). Conclusão: Validou-se um modelo de obesidade induzida por dieta hiperlipídica associada à resistência à ação da insulina e à intolerância à glicose, em um período de 10 semanas. Arq Bras Endocrinol Metab. 2013;57(5):339-45 Descritores Obesidade; dieta hiperlipídica; resistência à insulina; intolerância à glicose; camundongos ABSTRACTObjective: Validate a model of high-fat diet-induced obesity, of low cost, easy reproducibility, that could express characteristics observed in human, and would enable subsequent therapy proposals. Materials and methods: Sixteen Swiss mice received a standard diet (DP) or high--fat diet (DH) for 10 weeks. Results: Although the DP group had greater water (p < 0.01) and feed (p < 0.001) consumption, the DH group had greater body weight (p < 0.5) and adipose tissue gain (p < 0.001), favoring higher adiposity index (p < 0.001), glucose (p < 0.01), and area under the curve in the insulin (p < 0.001) and glucose (p < 0.01) tolerance tests. Conclusion: A high-fat diet-induced obesity model has been validated, which was also associated with insulin resistance and glucose intolerance after a period of 10 weeks. Arq Bras Endocrinol Metab. 2013;57(5):339-45

No abstract

No abstract

The aim of this study was to investigate the effect of prophylactic use of nonsteroidal anti-inflammatory drugs (NSAID, i.e. Ibuprofen) on physical performance, vertical jump, muscle biomarkers, liver, kidney, acute pain and hydration status of participants in the 42 km Trail Running Challenge, a long-distance race integrated over mountain routes. The sample consisted of 20 males randomly divided into two groups: a control group (CG) and an experimental group (EG) with 12 completing the race (41.1±8.8 y; 75.7±12.1 kg) and included in the final analysis. The EG were administered an ibuprofen capsule (400 mg) fifteen minutes before the beginning of the race, and again after 5 hours of racing if the route was not yet complete. There were significant time main effects for creatine kinase (CK) (p=0.001; f Cohen=0.25), lactate dehydrogenase (LDH) (p<0.001; f Cohen=2.05), aspartate aminotransferase (AST) (p=0.002; f Cohen=1.53), creatinine (p=0.002; f Cohen=2.24), urea (p=0.001; f Cohen=2.25), heart rate (HR) (p<0.001; f Cohen=4.88) and pain scores (p<0.001; f Cohen=1.93) which all increased during the race. There was a group × time interaction for squat jump (SJ) which significantly decreased in only the CG (p= 0.045; f Cohen=2.17). This may have been related to increased frequency of pain reported after the race in the gastrocnemius of the CG compared to the EG (p<0.05). It was concluded that ibuprofen intake did not reduce muscle damage during the competition but maintained leg muscular power performance (i.e. vertical jump), possibly by reducing gastrocnemius muscle pain.

Chrysobalanus icaco L. is a medicinal plant present in the Brazilian coastline and known for its hypoglicemic and antioxidant properties. Here, we assessed the beneficial metabolic effects of the aqueous extract of C. icaco (AECI) leaves in diet-induced obese mice. Swiss mice were fed standard chow (SC used as controls) or high-fat diet (HFD) to induce obesity. After 10 weeks, mice on each diet were divided into two groups with one group used as control while the other group treated with AECI for 4 weeks resulting in four groups of mice: SC; SC treated with AECI (SC + AECI); HFD; and HFD treated with AECI (HFD + AECI). AECI was administered drinking water at about 200 mg/kg. AECI was able to normalize insulin (13,682 ± 1090 vs. 9828 ± 485 AU, P < .05) and fasting blood glucose (192.8 ± 14.2 vs. 132.3 ± 6.4 mg/dL, P < .05) and inhibit weight gain (39 ± 5.7%) and fat storage in liver (72.60 ± 3.83%, P < .0001), despite the high-fat intake. These findings reinforce the use of AECI in hyperglycemia and highlight the potential extract's effect in preventing weight gain and fat accumulation in liver of diet-induced obese mice.

No abstract

No abstract